Richard A. Larson to Proto-Oncogene Proteins c-kit
This is a "connection" page, showing publications Richard A. Larson has written about Proto-Oncogene Proteins c-kit.
Connection Strength
0.224
-
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood. 2013 Jan 10; 121(2):385-91.
Score: 0.105
-
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006 Aug 20; 24(24):3904-11.
Score: 0.068
-
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
Score: 0.028
-
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214.
Score: 0.023